Amylyx (AMLX) CEO Joshua B. Cohen Sells Shares

What Happened

• Joshua B. Cohen, CEO of Amylyx Pharmaceuticals (AMLX), sold a total of 30,464 shares on Sept. 10, 2026, generating approximately $980,504 in proceeds.
  • 29,545 shares sold at a weighted-average price of $32.16 for ~$950,040 (sales executed across prices from $31.81 to $32.73).
  • 919 shares sold at a weighted-average price of $33.15 for ~$30,464 (sales executed across prices from $32.855 to $33.27).
• These were sales (not purchases). The larger block of shares was sold to cover tax withholding obligations tied to the vesting of performance stock units, and the sales were automatic rather than discretionary.

Key Details

• Transaction date: 2026-09-10; Form 4 filed 2026-09-14 (within the typical two-business-day filing window).
• Prices: weighted averages $32.16 (29,545 shares; range $31.81–$32.73) and $33.15 (919 shares; range $32.855–$33.27).
• Proceeds: about $980,504 total.
• Footnotes: F1 indicates the sale of shares to satisfy tax withholding on vested performance stock units (automatic). F2 and F3 note the reported prices are weighted averages across multiple trades; breakdowns by individual trade price can be provided to the SEC on request.
• Shares owned after the transaction are not specified in the provided excerpt of the filing.

Context

• Sales made solely to cover tax withholding on vested awards are routine and are automatic (not necessarily a signal of insider sentiment). This filing documents dispositions rather than optional exercises or discretionary open-market selling.